800 CHESAPEAKE DRIVE, REDWOOD CITY, CA
Reports Positive Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia and Business Update
Ex-99.1
Shareholder votes
Investor Presentation
CFO Departure - Vishwas Setia Separated from MapLight Therapeutics
Reports First Quarter 2026 Financial Results and Provides Business Update
Board Changes - Dr. Malenka and Dr. Trenkle Not Standing for Reelection
Annual Report to Security Holders
Q2
FY 2025
Q3
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Registration of Securities
Certificate
Amended Registration Statement for Securities
S-1
Definitive Proxy Statement
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Free Writing Prospectus